Biosimilars

Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment

Abstract The American Association of Pharmaceutical Scientists (AAPS) biosimilar focus group on nonclinical and clinical assays has developed this manuscript to guide the industry on…

Find Out More

Webinar on Demand: Recent Aspects and Challenges in the Assessment of Immunogenicity

  • External Link

The assessment of immunogenicity of biological protein drugs is a key component in drug development. A basic knowledge in immunology is a prerequisite for understanding…

Find Out More

Systematic Verification of Bioanalytical Similarity Between a Biosimilar and a Reference Biotherapeutic: Committee Recommendations for the Development and Validation of a Single Ligand-Binding Assay to Support Pharmacokinetic Assessments

Published by The AAPS Journal Abstract For biosimilar drug development, it is critical to demonstrate similar physiochemical characteristics, efficacy, and safety of the biosimilar product…

Find Out More

Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab

Ebbers HC1, van Meer PJ, Moors EH, Mantel-Teeuwisse AK, Leufkens HG, Schellekens H. Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab.…

Find Out More

Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development

Abstract Biopharmaceutical products (biologics) are active drug substances produced by living cells or derived from a living organism (bacteria, yeast, animal or human cell lines).…

Find Out More

Biosimilars: what clinicians should know

Weise M et al. Blood. 2012;120:5111-7. Abstract Biosimilar medicinal products (biosimilars) have become a reality in the European Union and will soon be available in the…

Find Out More

Setting the stage for biosimilar monoclonal antibodies

Schneider CK et al. Setting the stage for biosimilar monoclonal antibodies. Nature Biotech. 2012;30:1179-85. Abstract With the first marketing authorization application for a biosimilar monoclonal…

Find Out More